{"id":"W4387810156","doi":"10.1016/j.annonc.2023.09.2830","title":"375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Oncology; De-escalation; Solid tumor; Internal medicine; Nuclear medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001074507,0.001696364,0.001451281,0.0005198863,0.0004795502,0.001266583,0.000843862,0.0009445443,0.004550063],"category_scores_gemma":[0.0005116518,0.0006296743,0.001213272,0.0004923097,0.001062854,0.0007806125,0.0003297614,0.00346785,0.001123959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002268111,"about_ca_system_score_gemma":0.002172664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004308056,"about_ca_topic_score_gemma":0.009757021,"domain_scores_codex":[0.9995804,0.0001447973,0.00001587632,0.00007623822,0.00004185582,0.0001408272],"domain_scores_gemma":[0.9996592,0.00003443223,0.00004076582,0.00003529788,0.00001766732,0.0002126949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6134376,0.09536774,0.01155182,0.0005661638,0.001917165,0.0003311023,0.000501413,0.008324708,0.09231748,0.0009694584,0.01252233,0.162193],"study_design_scores_gemma":[0.5302104,0.4334875,0.01482662,0.00003609855,0.0005490801,0.0002745009,0.0001258986,0.003414431,0.009473138,0.0004594229,0.007087613,0.0000554141],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904394,0.001192413,0.0007212577,0.0006652149,0.0001643073,0.002051856,0.002049623,0.0001786952,0.002537155],"genre_scores_gemma":[0.9872102,0.001088052,0.002101754,0.0008744698,0.0001091885,0.001359181,0.003466977,0.00005458332,0.003735684],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004550063,"threshold_uncertainty_score":0.01645637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03419545992318253,"score_gpt":0.4102452826055652,"score_spread":0.3760498226823827,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}